Please assess the completion status of the following clinical trial:

Trial Title: Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent prior to beginning protocol specific procedures~* Male or female \> 18 years of age~* Histologically proven diagnosis of adenocarcinoma of the stomach~* HER2 negative tumor or HER2+ tumors not qualifying for herceptin therapy~* Locally advanced (non resectable) or metastatic gastric cancer~* Presence of measurable disease with at least one measurable lesion by means of CT scan or MRI in not previously irradiated area(s) (according to RECIST criteria (version 1.1)~* Life expectancy of \>/= 3 months~* ECOG performance status of 0-2 at study entry~* Neutrophils \>/= 2.0 x 1000000000/L, platelets \>/= 100 x 1000000000/L, and hemoglobin \>/= 10 g/dL~* Bilirubin level either normal or \</= 1.5 x ULN~* AST and ALT \</= 2.5 X UNL (\</= 5 x ULN if liver metastasis are present~* Alkaline phosphatase (ALP) \</= 2.5 X ULN; patients with alkaline phosphatase \> 2.5x ULN and AST and ALT \</= 1.5 x ULN are equally eligible~* Serum creatinine \< 1.5 x ULN. In presence border-line values, the calculated creatinine clearance should be \>/= 60 mL/min~* Negative pregnancy test (if female in reproductive years)~* Effective contraception prior to study entry and for the duration of the study participation, for both male and female patients of child producing potential~* Able and willing to comply with scheduled visits, therapy plans and laboratory tests required in this protocol~Exclusion Criteria:~* Previous chemotherapy, except adjuvant treatment administered at least 1 year before study entry~* Concurrent chronic systemic immune therapy~* Any investigational agent(s) 4 weeks prior to entry~* Clinically relevant coronary artery disease or a history of a myocardial infarction or a history of hypertension not controlled by therapy within the last 12 months~* Known hypersensitivity to study drugs. Known grade 3 or 4 allergic reaction to any of the components of the treatment~* Known drug abuse/ alcohol abuse~* Acute or subacute intestinal occlusion and any other significant chronic gastrointestinal disease that might interfere with absorption of oral treatment~* History of clinically relevant psychiatric disability precluding informed consent~* Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Pregnant or breastfeeding women~* Active uncontrolled infection(s)~* Positive for HIV serology and/or viral hepatitis B or C~* Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel & Oxaliplatin & Capecitabine (Type: EXPERIMENTAL): Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)
- Epirubicin & Oxaliplatin & Capecitabine (Type: EXPERIMENTAL): Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).